Skip to content

Plantar Pressure and Acceptance of the LEEF-shoe in Individuals With Diabetes-related Neuropathy

Plantar Pressure and Acceptance of the LEEF-shoe in Individuals With Diabetes-related Neuropathy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07488104
Acronym
LEEF-shoe
Enrollment
30
Registered
2026-03-23
Start date
2026-04-01
Completion date
2027-01-01
Last updated
2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Neuropathy

Keywords

orthopaedic footwear, Diabetes Mellitus, Diabetic foot, Wearing time, Plantar pressure

Brief summary

Rationale: Of all individuals with diabetes, 19-34% develop a foot ulcer in their lifetime, and nearly 25% of these ulcers result in amputation. Ulcer prevention is often addressed by prescribing orthopedic shoes (OS). However, the effectiveness of OS is highly dependent on the individual shoe technician's skill and experience, and OS is frequently perceived as unattractive by users. To overcome these limitations, the LEEF-shoe was developed. It eliminates the need for a fully individualized shoe technician approach by using a standardized protocol to determine the rocker settings. This may provide comparable plantar pressure relief, while potentially improving patient acceptance due to its more appealing design and simplified prescription process. Objective: The primary objective is to determine whether the LEEF-shoe differs from standard-OS in terms of plantar pressure distribution. Secondary objectives are evaluation of wearing time and user acceptance of both footwear types. Study design: This study is a randomized cross-over trial. Participants will complete pre- and post-tests for plantar pressure distribution, wearing time will be measured, and focus group sessions will assess user experience and acceptance. Study population: A total of 30 adults (≥18 years old) with diabetes mellitus and peripheral neuropathy, at increased risk for foot ulceration, will be included. Intervention: All participants will receive two pairs of OS, a standard-OS and an additional OS (e.g., the LEEF-shoe), both provided through usual care channels. At handover, plantar pressure measurements will be performed. Participants will then wear each shoe model for four weeks, one after the other, with wearing time continuously monitored. Following the 8-week period, participants return for a standard control appointment with the OS-technician, during which post-test pressure measurements are taken. Subsequently, participants are allowed to wear either shoe based on personal preference for an additional four weeks, during which wearing time continues to be recorded. The study concludes with focus group sessions to explore experiences and acceptance. Main study parameters/endpoints: The primary outcome of the study is peak plantar pressure. It will be compared between the standard-OS and LEEF-shoe during the randomization visit. The secondary outcomes are peak plantar pressures in 7 foot regions, wearing time of the OS and user experience and acceptance, assessed through semi-structured focus groups. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Participants will be screened for eligibility during their regular consultation with the prescribing physician and OS-technician. After inclusion, participants will follow standard care procedures, which include an initial shoe fitting, a midway fitting, the handover of both shoes, and two follow-up appointments. To minimize any potential risk associated with wearing the LEEF-shoe at home following the handover, it is required that the LEEF-shoe is at least equivalent to, or better than, the standard-OS in terms of function and safety. Since the LEEF-shoe is produced within the existing framework and standards of OS manufacturing, it is considered a variant of standard-OS and thus falls within the boundaries of standard care.

Interventions

DEVICELEEF-shoe

The LEEF-shoe is a variant of a standard-OS and therefore follows identical classification. The LEEF-shoe is classified as custom-made medical devices under EU Medical Device Regulation (MDR), as they are prescribed in writing, designed with specific characteristics, and intended for the exclusive use of an individual patient. Consequently, they are exempt from CE-marking requirements. The processes at STEPP BV for these custom-made medical devices are ISO 13485 certified. This certification is also required for the production of medical devices. These processes are governed by Standard Operating Procedures (SOP), which describe how the process is to be carried out. The LEEF-shoe utilizes a rocker algorithm (simple search) to optimize the shape. Both ways of producing OS (Standard-OS \& LEEF-shoe) fit in the SOPs of STEPP BV, following ISO 13485. Standard-OS shoes typically consist of a supplement onto which the outsole is attached. The upper encloses the supplement. The suppleme

DEVICEstandard orthopaedic shoe

The standard orthopaedic shoe, which is the care as usual solution in the Netherland. ISO 13485 certified and optimized individually.

Sponsors

University Medical Center Groningen
Lead SponsorOTHER
Amsterdam UMC
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Aged 18 years or older * Diabetes mellitus type 1 or 2 * IWGDF Risk 2 - 3 * Prescribed with fully custom-made orthopedic footwear (OS type A) * Ability to provide informed consent

Exclusion criteria

* Severe foot deformities * Active Charcot's neuroarthropathy * Foot ulcer or open amputation site * Severe illness, based on clinical judgment by the physician * Not able to walk at least 10 meters uninterrupted

Design outcomes

Primary

MeasureTime frameDescription
In-shoe peak plantar pressuremeasured during the handover of both shoes, before the wearing periods.Measured with the Pedar-X measurement system

Secondary

MeasureTime frameDescription
In-Shoe peak plantar pressuremeasured after the two wearing time periods (totalling 8 weeks)Measured with the Pedar-X measurement system
Wearing timecollected during the three subsequent wearing periods of four weekswearing time (adherence) measured with a orthotimer in each shoe
Shoe massmeasured during the handover of both shoes, before the wearing periodsThe weight of both pair of orthopedic shoes.
Body massAfter enrollment, baselineThe weight of the participant.
Focus groupAfter completion of the total protocol, after 12 weaks of wearing the ortopedic shoes.Semi-structured interview regarding acceptance.
Participant heightAfter enrollment, baselineHeight of the participant.
Participants foot lengthAfter enrollment, baselinethe length of the feet of the participants.

Countries

Netherlands

Contacts

CONTACTJelmer Braaksma, PhD
j.braaksma01@umcg.nl+31 6 24665798
CONTACTJuha M Hijmans, PhD
j.m.hijmans@umcg.nl+31 (0)6 55256225

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 24, 2026